Valeant eyes smaller deals to build on Salix, Dendreon purchases

Valeant Pharmaceuticals International Inc will use its acquisitions of Salix Pharmaceuticals Ltd and assets of Dendreon Corp for smaller deals that fit into those businesses, Chief Executive Officer Michael Pearson said on Monday. Laval, Quebec-based Valeant on Sunday announced its largest-ever acquisition, the $10.1 billion cash purchase of Salix, known for its drug Xifaxan to treat irritable bowel syndrome.

Here is the original post:
Valeant eyes smaller deals to build on Salix, Dendreon purchases